Movement Alert｜AKESO Intraday Rise 3.65% in Regular Trading, ESMO data and priority review expectations support sentiment

Market Focus10-28

On October 28, AKESO rose 3.65% in regular trading, with the stock trading at HK$83.6 and turnover of HK$105 million.

The move was accompanied by renewed attention on the company’s ivonescimab program after its phase III HARMONi-GI1 study in first-line advanced biliary tract cancer delivered positive results, was selected for an ESMO Presidential Symposium oral presentation, and the indication had previously been proposed for priority review.

According to the disclosed details, HARMONi-GI1 is a randomized, controlled, double-blind, registrational phase III trial enrolling 682 patients. The company also said ivonescimab has now advanced into more than 60 phase II/III studies, including 18 global phase III trials, reinforcing market focus on the depth of its core pipeline and potential commercialization pathway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment